# Arginetix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arginetix

- Industry: Pharmaceuticals
- Headquarters: Lutherville, US
- Total disclosed funding: $22M
- Latest round: Series A (Jun 13, 2010)
- Investors on record: 8

## About

Arginetix is based in Lutherville, US and is a bio-pharmaceutical company dedicated to developing and commercializing novel therapeutic small molecule inhibitors of arginase.

## Funding rounds

- Series A, Jun 13, 2010, $15M — Domain Associates, Quaker Partners Management, Ben Franklin Technology Partners, Red Abbey, NewSpring, MedImmune Ventures, Acidophil, Maryland Health Care Product Development Corporation
- Series B, Nov 2, 2009, $4.6M — Quaker Partners Management, Red Abbey, MedImmune Ventures, Acidophil, Maryland Health Care Product Development Corporation
- Angel, Oct 23, 2008, $2.3M — Quaker Partners Management, Red Abbey, MedImmune Ventures, Acidophil

## Investors

- Quaker Partners Management (https://capitalatlas.ai/funds/quaker-partners-management) — Angel, Series B, Series A
- Red Abbey (https://capitalatlas.ai/funds/red-abbey) — Angel, Series B, Series A
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Angel, Series B, Series A
- Acidophil — Angel, Series B, Series A
- Maryland Health Care Product Development Corporation — Series B, Series A
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A
- Ben Franklin Technology Partners (https://capitalatlas.ai/funds/ben-franklin-technology-partners) — Series A
- NewSpring (https://capitalatlas.ai/funds/newspring) — Series A